Xerion Pharmaceuticals AG and Stemline Therapeutics Announce Collaboration on Cancer Stem Cells
10-Jun-2004
Munich and New York. Xerion Pharmaceuticals AG and Stemline Therapeutics, Inc. have entered into a collaborative agreement
under which the two privately-held companies plan to identify novel protein targets expressed
on cancer stem cells. Under the terms of the agreement, Xerion will apply its
Xstream® technology to Stemline's proprietary cancer stem cell platform (Stem-
Screen(TM)) to identify novel and druggable oncology targets. The companies will share
equally and have the option to co-develop any targets arising from this collaboration.
Xerion's Xstream® technology has been applied to human cancer cells and has successfully
generated a number of cancer-relevant targets. This has led to the development
of fully human antibody therapeutics against some of these targets. Stemline,
together with its collaborator Dr. Malcolm Moore of the Memorial Sloan-Kettering Cancer
Center, who previously led the team that discovered human G-CSF (later, Neupogen
®), have built a proprietary and comprehensive cancer stem cell platform. Cancer
stem cells are a highly virulent subpopulation of tumors important in the development
and persistence of malignancy.
"We are excited about applying our Xstream® technology to Stemline's platform" said
Markus Ewert, Ph.D., President and CEO of Xerion. "We believe that screening
against cancer stem cells will enable us to find new, druggable targets for cancer. We
look forward to working with Stemline, a leader of this rapidly emerging cancer stem
cell space".
"Stemline is especially pleased to have integrated its cancer stem cell platform with
Xerion's robust and validated Xstream® technology", explained Ivan Bergstein, M.D,
CEO of Stemline. "We expect that this landmark collaboration will lead to the identification
of important oncology targets and the development of the first pipeline of drug
candidates that target cancer stem cells".
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Novartis: PTK/ZK CONFIRM 1 Study Shows Positive Drug Effects in Phase III Study in Metastatic Colorectal Cancer
Bausch & Lomb and Galapagos sign agreement to collaborate on ophthalmic disease research
Phytopathology
Caught by a hair - Crime fighters could have a new tool at their disposal
BBCH-scale_(leafy_vegetables_not_forming_heads)
AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing
Silence Therapeutics' Group CEO resigns
BBCH-scale_(other_brassica_vegetables)
Deublin GmbH - Hofheim am Taunus, Germany
